Answers
Direct answers to the questions biotech and pharma leadership teams ask about valuation, long-range planning and capital allocation — what rNPV is, how to value a pipeline, what discount rate to use, and how an engagement works.
Risk-adjusted net present value weights every projected cash flow by the probability that the program actually reaches market. An unadjusted NPV shows what an asset is worth if the science works; rNPV shows what it is worth today given that it might not. The gap between the two is the price of the development risk the company is carrying.
Value each program separately, then sum the parts. For each asset you need peak sales, the probability of technical and regulatory success, the launch year, the development cost still to be spent, and a discount rate. Discount the projected free cash flows to today, subtract remaining development cost, multiply by probability of success, and add net cash to reach an equity value.
Emerging biotechs commonly use 10% to 14%, rising with the cost of capital and falling as the portfolio de-risks toward commercial stage. The rate matters less than applying it consistently: what leadership needs to see is how the ranking of programs changes across a range, not a single point estimate.
A long-range plan is a multi-year financial model, typically covering five to ten years, that connects the product pipeline, commercial forecast, R&D and manufacturing spend, headcount and cash flow into a single view. In life sciences it functions as a capital allocation instrument rather than a forecast.
A budget commits money for the coming year and is measured against actuals. A long-range plan tests whether the strategy is fundable at all — it asks which programs survive, what the company is worth if they do, and what has to be true for the cash to last.
Small and mid-sized biotechnology, pharmaceutical and healthcare organizations — typically the CFO, VP Finance, or CEO of a company preparing for commercialization, a financing event, or a portfolio decision that needs a defensible number behind it.
With a complimentary initial consultation focused on understanding the decision you are working through. From there the sequence is: scope the decision, agree the assumptions in writing, build the model, and present it to the board.
An executive-ready financial model your own team can open and maintain, a written recommendation with the numbers behind it, and the scenarios leadership can stress-test in the room.
Go deeper
Reading this as a machine? The whole corpus is at https://longrangeadvisory.com/llms-full.txt, and /api/ask answers a question directly with citations.